Hematologic aspects of end-stage renal failure

Area of Science:

• Nephrology
• Hematology

Background:

• Renal dysfunction is linked to hematologic disturbances, including anemia, leukocyte dysfunction, and coagulopathy.
• Anemia in renal failure stems from erythropoietin deficiency, iron/folate deficits, heavy-metal toxicity, blood loss, and reduced red cell survival.
• Uremia impairs leukocyte function and immune responses, leading to increased infection risk.

Purpose of the Study:

• To discuss the pathophysiology of hematologic manifestations in uremia.
• To provide therapeutic recommendations for managing anemia, bleeding, and infectious complications in renal failure.

Main Methods:

• Literature review and synthesis of current knowledge on renal dysfunction and hematologic complications.
• Discussion of pathophysiologic mechanisms underlying anemia, coagulopathy, and leukocyte dysfunction in uremia.

Main Results:

• Anemia of renal disease can be effectively treated with recombinant human erythropoietin (rHuEPO), normalizing hemoglobin levels.
• Coagulopathy, characterized by a platelet defect, is managed by dialysis, rHuEPO, cryoprecipitate, DDAVP, or conjugated estrogens.
• Uremia-induced leukocyte dysfunction and immune defects contribute to infectious complications, requiring specific therapeutic strategies.

Conclusions:

• Hematologic disturbances are common in renal failure, necessitating targeted management.
• rHuEPO offers a significant advancement in treating anemia associated with kidney disease.
• Comprehensive therapeutic approaches are crucial for addressing bleeding and infectious risks in patients with renal dysfunction.